Policy

Latest News


CME Content


Ongoing shortages of common oncology chemotherapies have compelled physicians to substitute more expensive drugs, delay or suspend clinical trials, or even skip doses of chemotherapy, according to survey results gathered by a team from the University of Pennsylvania.

Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that in regard to payers impacting the use of immunotherapies, most payers have decided they will respect the judgment of the Food and Drug Administration, Centers for Medicare & Medicaid Services and the National Comprehensive Cancer Network.

The panel at the American Thoracic Society 2013 International Conference continued discussions that suggested high rates of hospital readmissions may be an indicator of poor initial treatment, or failure to coordinate care. Further, these rates, which varied dramatically from hospital to hospital, were often excessively expensive.

David H. Au, MD, MS, kicked off the Hospital Readmissions session at the American Thoracic Society 2013 conference with his presentation on Defining the Role of the Practitioner, Scientist and Policymaker. In the presentation, Dr Au says that it is important for all stakeholders in the healthcare industry to focus on hospital readmission rates.

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo